Introduction
The phosphodiesterase (PDE) 5-inhibitor, sildenafil citrate (Viagra), provides welltolerated pharmacotherapy for erectile dysfunction (1) . PDE5 is responsible for guanosine 3', 5' cyclic monophosphate (cGMP) degradation (2) . Nitric oxide (NO), derived from nitric oxide synthase (NOS), stimulates soluble guanylate cyclase to generate intracellular cGMP (3) . Elevated levels of cGMP, following PDE5 inhibition or NO stimulation, cause protein kinase (PK) G-dependent smooth muscle relaxation (3, 4) . The consequent vasodilator activity is the basis of improved erectile function (1) .
Features of asthma and chronic obstructive pulmonary disease (COPD) include bronchoconstriction, airway hyperreactivity (AHR), increased exhaled NO and pulmonary inflammation, characterised by eosinophil and neutrophil influx, respectively (5, 6, 7) . Elevated intracellular levels of adenosine 3', 5' cyclic monophosphate (cAMP) produced by inhibition of cAMP degradation via PDE4 or by β 2 -adrenoceptor-mediated stimulation of adenylyl cyclase, causes PKC-and PKGdependent bronchodilation (8) and suppression of inflammatory cell activity (9, 10, 11, 12) . Consequently, elevating cAMP levels with PDE4 inhibitors such as rolipram have been shown to reduce the airway inflammation, AHR and early and late asthmatic responses induced by allergen challenge in animal models (9, 13, 14, 15, 16) . They have also been shown to alleviate some of the symptoms associated with asthma (17) and COPD (18) and is the basis of their potential use in treating severe asthma and COPD (18, 19) . 4 In primary airway epithelial cells, PDE4 and PDE5 predominate, hydrolysing [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] and 80 % of the total cAMP and cGMP, respectively (20) . Cross-talk exists between cAMP and cGMP, since cAMP also inhibits PDE5 thereby allowing cGMP levels to rise, and both cAMP (8) and cGMP to activate PKG (4) . Further similarities between the inhibitory activities of cAMP and cGMP on microvascular leakage (8, 13, 19) and inflammatory cell activity (2, 19, 21) , raises the possibility of novel drug targets for asthma and COPD treatment via cGMP regulation.
Sildenafil selectively inhibits PDE5 with 80 to 8500-fold greater affinity than PDE 1-4 isozymes, and with 240-fold greater potency than the earlier generation PDE5-inhibitor, zaprinast (22) . The first aim of this study was to examine the effects of sildenafil in two well-characterised conscious guinea-pig models, whereby exposure to lipopolysaccharide (LPS) induces neutrophil-dominated inflammation and airway hyperreactivity similar to COPD (10, 12, 23) or exposure of atopic guinea-pigs to allergen causes features of asthma (9, 24) . In these models of inflammation, wholebody plethysmography was used to monitor airway function, AHR was assessed to inhaled histamine, and bronchoalveolar lavage fluid was removed to determine levels of leukocyte infiltration and NO (metabolites) production in the airways. The second aim of this study, since the effectiveness of sildenafil to reverse erectile dysfunction is NO-dependent, was to evaluate whether any beneficial effects of sildenafil in these models were NO-dependent. Using the non-selective NOS-inhibitor, N ω -nitro-Larginine methyl ester (L-NAME), to inhibit NO synthesis, the beneficial effects of sildenafil treatment on the lung following exposure to LPS were evaluated in the absence of airways NO (23) . In this study, it is reported for the first time that the PDE5-inhibitor, sildenafil (Viagra™), inhibits inflammation and airways reactivity in 5 animal models of airways diseases and therefore may have therapeutic potential in the treatment of asthma and COPD.
Materials and Methods (Full details are available at the online-only Repository) (Word count 550)
Airway function (specific airways conductance: sG aw ) was monitored in conscious Dunkin-Hartley guinea-pigs (male, 300 -400 g), using whole body plethysmography (25) to measure airflow across a pneumotachograph and box pressure with a Biopac data acquisition system and AcqKnowledge software.
Guinea-pigs actively sensitised with ovalbumin (OA, i.p., 10µg) and aluminium hydroxide (100mg) received nebulised OA (100 µg.ml -1 , 1h) or pathogen-free saline 14 days later. Non-sensitised guinea-pigs were exposed to nebulised LPS (30 µg.ml -1 , 1h) or pathogen-free saline. sG aw was measured prior to OA or LPS exposure and at regular intervals up to 12h and at 24h afterwards. Sildenafil (1 mg.kg -1 ), based on human oral doses (26) , or pathogen-free saline were administered (i.p.) 24 and 0.5h before OA, LPS or saline exposure. OA-exposed animals were further treated at 6h.
Nebulised L-NAME (12mM, 15 min) (27) . was delivered to untreated or sildenafiltreated non-sensitized animals or at 105 min after completing exposures to LPS or vehicle. Airway hyperreactivity was assessed with a threshold dose of nebulised histamine (1mM, 20s) which 24h before challenges gave negligible bronchoconstriction. This was repeated in the same animal 24h after OA or 1 or 4h
after LPS exposure. Bronchodilator activity of sildenafil was assessed with a higher bronchoconstrictor dose of inhaled histamine (3mM, 20s) administered before and after sildenafil treatment. sG aw was measured before and at 0, 5 and 10 min after histamine exposures. 24h after exposure to OA and 1, 4 or 24h after LPS (or their saline equivalents), animals were overdosed with pentobarbitone sodium for bronchoalveolar lavage (BAL) to determine total (cells.sample -1 ) and differential cell counts (macrophages, eosinophils and neutrophils) after cytospin centrifugation and staining with
Leishman's stain (1.5 % in 100 % methanol).
The remaining BAL fluid was centrifuged (1200 r.p.m., 6 min) and the supernatant frozen (-70 °C) for determination of nitrite and nitrate by the Griess reaction (28) as previously described (10) . BAL fluid (100µl) was incubated (37°C) for 30 min with HEPES buffer (50mM, pH 7.4), FAD (5µM), NADPH (0.1mM), distilled water (290µl) and nitrate reductase (0.2 U.ml -1 ) for the conversion of nitrate to nitrite.
Nitrate reductase was omitted for nitrite determination. cGMP generation in lungs from saline-or sildenafil-treated animals was measured in chopped lungs suspended in phosphate-free Krebs solution (0.3mg.ml -1 ), gassed with 5%CO 2 /95%O 2 at 37 o C. S-Nitroso-N-acetylpenicilliamine (10 -3 M) was added for 20 min and the reaction terminated by adding 0.5ml of the suspension to 0.5ml HCl (1N), which was homogenised (20,000 R.P.M., 20s) and centrifuged (13,000 r.p.m., 3 7 min). Supernatant cGMP levels were determined by enzyme-linked immunosorbent assay (ELISA) and expressed as pmol.mg -1 of wet-lung weight.
Mean changes in sGaw are presented as a percentage of the baseline value preceeding a challenge. BAL fluid cell counts and NO metabolites were compared using Analysis of Variance, followed by Scheffe's post hoc analysis. Airway function was compared using Analysis of Variance over the entire time course followed by paired or unpaired Student's (two-tailed) t-test. Differences were considered significant when P<0.05. 
Results

Effect of sildenafil treatment on cGMP generation in isolated chopped lung
Airway reactivity to inhaled histamine
Inhaled histamine (1mM, 20s, nose-only) prior to saline or OA exposure failed to cause a significant bronchoconstriction (Figure 2A and 2B). At 24h after saline exposure, the airway responsiveness to histamine (1mM, 20s) was not significantly different (P>0.05) to before saline ( Figure 2B ). However, at 24h after exposure to OA, there was a significant (P<0.01) bronchoconstriction to inhaled histamine (1mM, 20s), indicating AHR ( Figure 2A ). Treating the OA-sensitised guinea-pigs with vehicle failed to affect the development of AHR at 24h after OA exposure ( Figure   9 2B). However, in OA-sensitised guinea-pigs treated with sildenafil there was no significant difference between inhaled histamine responses before and 24h after OA exposure, indicating that the AHR was inhibited ( Figure 2B ). There was no AHR to histamine in sildenafil-treated sensitized guinea-pigs before OA exposure. A higher dose of inhaled histamine (3mM, 20s) that produces a significant bronchoconstriction (-17.2 + 11.8 mean % decrease from baseline sG aw , respectively) (P<0.01) was used 24h before sildenafil treatment and saline exposure ( Figure 2B , histogram C). When repeated after treating with sildenafil and 24h after saline exposure, the bronchoconstriction (-17.6 + 11.9 %) was not significantly (P>0.05) altered.
Leukocyte infiltration
OA-sensitised guinea-pigs exhibited increased levels of macrophages in the BALF compared with non-sensitised guinea-pigs ( Figure 3A) . Exposure of OA-sensitised guinea-pigs to saline failed to affect the levels of leukocytes in the airways at 24h, and the cellular content of the BALF was not significantly (P>0.05) different from that observed before exposure, in naïve OA-sensitised animals ( Figure 3A ). Treating saline-exposed OA-sensitised animals with sildenafil also failed (P>0.05) to affect the levels of BALF leukocytes, compared with naïve OA-sensitised guinea-pigs 
Nitric Oxide
The variation in concentrations of the individual NO metabolites (nitrate and nitrite)
in BALF were synchronous. However, as described previously (23), lower levels of nitrate were analysed due to the rate limiting nitrate reductase conversion of nitrate to measurable nitrite (data not shown). Therefore, to describe changes in the NO metabolite levels, the combined nitrate and nitrite values are shown in Figure 3B .
At 24h after exposing OA-sensitised guinea-pigs to saline, there was no significant (P>0.05) difference in the levels of BALF NO metabolites, compared to naïve OAsensitised animals ( Figure 3B ). However, at 24h after exposure to OA, the BALF NO metabolites were significantly elevated. Treating the OA-exposed animals with vehicle failed (P>0.05) to alter the significant increase in combined NO metabolites (159.3 + 14.6 µM.100µl of BALF sample -1 ) at 24h ( Figure 3B ). However, treatment with sildenafil significantly reduced the raised NO metabolite levels at 24h after OA challenge by 48% (P<0.05)( Figure 3B ). Interestingly, treating saline-exposed animals with sildenafil caused a 73% rise in combined NO metabolites at 24h, compared with exposure to saline only ( Figure 3B ).
Effect of sildenafil after LPS exposure
Airway function
Exposure of non-sensitised guinea-pigs to LPS (30 µg.ml 
Airway reactivity to inhaled histamine
Inhalation of a threshold dose of histamine (1mM,) before saline or LPS exposure failed to produce a significant bronchoconstriction ( Figure 5A ). 24h later, at 1h after saline there was no change in reactivity ( Figure 5A , histogram A). However, at 1h
after LPS exposure, in guinea-pigs treated with the sildenafil vehicle, there was a significant bronchoconstriction to inhaled histamine (1mM)( Figure 5A , histogram B).
The reactivity to histamine had recovered by 4h after the LPS challenge ( Figure 
Leukocyte infiltration
Exposure of non-sensitised guinea-pigs to saline failed to significantly affect the BALF levels of leukocytes in the airways at 24h (P>0.05) compared with naïve nonsensitised animals ( Figure 6A ). Treating saline-exposed animals with sildenafil also failed (P>0.05) to alter the BALF leukocyte content, from that observed in naïve 
Nitric oxide
The combined BALF NO metabolites removed at 24h after exposing non-sensitised guinea-pigs to saline, were not significantly (P>0.05) different from that removed from naïve non-sensitised animals ( Figure 6B ). However, in guinea-pigs exposed to LPS or treated with vehicle and exposed to LPS, NO metabolite levels were significantly elevated at 24h ( Figure 6B ). Treating saline-exposed guinea-pigs with sildenafil failed to alter the levels of NO metabolites in BALF ( Figure 6B ). However, treating LPS-exposed animals with sildenafil, significantly attenuated the raised NO metabolite levels at 24h, by 59 % (P<0.01)( Figure 6B ).
Effect of inhibiting NOS with L-NAME on the activity of sildenafil
Airway function after exposure to L-NAME Airway reactivity to inhaled histamine after exposure to LPS followed by L-NAME 2h after exposure to nebulised LPS, guinea-pigs were further exposed to inhaled L-NAME. A further 2h later (4h after LPS), exposure to inhaled histamine (1mM)
revealed AHR ( Figure 5B , histogram F). This contrasts with the lack of AHR to histamine, at 4h after exposure to LPS alone ( Figure 5A , histograms D). There was no AHR to inhaled histamine (1mM) 4h after exposure to saline and 2h after exposure to L-NAME ( Figure 5B , histogram E). In animals treated with sildenafil, the inhaled histamine (1mM) responses before and 4h after exposure to LPS followed by L-NAME were not significantly different ( Figure 5B , histogram G). Thus, sildenafil inhibited the extension of AHR by L-NAME to 4h after LPS exposure. The airway responses to the higher bronchoconstricting dose of inhaled histamine (3mM) before (-23.7 + 8.6 peak % change from baseline sG aw ) and 4h after exposing sildenafiltreated guinea-pigs to saline and (2h after) L-NAME (-28.6 + 9.2%) were not significantly (P>0.05) different ( Figure 5C , histogram I).
Leukocyte infiltration after exposure to LPS followed by L-NAME
Compared with naïve and saline-exposed animals (macrophages: 2.1 + 0.5 and neutrophils: 0.0 + 0.0), there was an increase in macrophages (6.5 + 3.5) and neutrophils (30.1 + 6.1, P<0.001) at 4h after LPS exposure ( Figure 7A ). Leukocyte levels in the BALF removed 4h after saline exposure, with or without L-NAME exposure at 2h, were not significantly (P>0.05) different from those observed in naive 14 animals ( Figure 7A ). Pre-treating of animals exposed to both saline and L-NAME with sildenafil also failed to significantly (P>0.05) affect the BALF leukocyte content at 4h. In guinea-pigs exposed to LPS, exposure to L-NAME at 2h caused a further increase in macrophages (24.4 + 5.9) at 4h, but not neutrophils (24.0 + 3.0)( Figure   7A ). In sildenafil-treated guinea-pigs, the increases in macrophages and neutrophils in the BALF removed at 4h after exposure to LPS and followed at 2h by L-NAME were significantly attenuated by 57 % (P<0.01) and 90 % (P<0.001), respectively ( Figure   7A ).
Airways nitric oxide after exposure to LPS followed by L-NAME
During the AHR at 1h after LPS exposure, there was a deficiency in the combined NO metabolites, which recovered to baseline levels at 4h ( Figure 7B ) along with recovery of airway reactivity ( Figure 5A , histogram D). Exposure to saline failed to affect the levels of NO metabolites at 1h ( Figure 7B ). L-NAME exposure, 2h after exposure to saline or LPS, inhibited the generation of NO metabolites at 4h ( Figure 7B ). However, in sildenafil-treated guinea-pigs exposed to LPS or saline followed by L-NAME, there was no deficiency in NO metabolites and levels of NO were increased above that found in naïve animals ( Figure 7B ).
Discussion
Exposure of atopic (OA-sensitised) guinea-pigs to aerosolised antigen (OA), caused the development of an EAR (0-6h) and LAR (7-11h), as reported previously by ourselves (24) and by others (13) . Treating the OA-sensitised guinea-pigs with sildenafil failed to affect the EAR or LAR. Allergen-induced mast cell degranulation BALF removed from OA-sensitised animals 24h after OA exposure revealed raised levels of eosinophils and macrophages, which were attenuated by sildenafil and could be attributed to the consequent elevated intracellular cGMP levels. Although eosinophils predominately express cAMP-specific PDE4 (2), elevated cGMP levels can indirectly increase the cAMP concentration, by directly inhibiting PDE3 degradation of cAMP (4, 30) . Therefore, in this study, sildenafil may have suppressed eosinophil influx via a cGMP-cAMP 'cross-talk' mechanism, causing an elevation in intracellular cAMP, which has been shown to suppress inflammatory cell activity (2, . TNF-α also stimulates the transcription of iNOS, responsible for NO over-production (33) . In LPS-exposed rats, inhibiting TNF-α attenuates AHR and neutrophil influx (36). Fuhrmann and coworkers (20) suggest that elevating cGMP down-regulates TNF-α expression, which would therefore suppress neutrophil influx and AHR. Thus, sildenafil, through raising intracellular cGMP levels, would attenuate this LPS-induced over-production of NO.
In confirmation of our previous studies (23) , during the LPS-induced AHR (1h after LPS), the generation of NO metabolites in the BALF, was reduced. The resolution of AHR coincided with a recovery in NO generation, 4h later. Inhibiting NO recovery with the non-selective NOS-inhibitor, L-NAME, prolonged AHR to at least 4h, suggesting the involvement of a NO-dependent mechanism in the recovery from LPSinduced AHR. L-NAME alone failed to cause AHR, indicating that NO-deficiency alone was not responsible for the LPS-induced AHR. Previous studies from this laboratory and by others, have also described this phenomenon of NO-deficiency during AHR followed by recovery, in comparable guinea-pig models of lung 18 inflammation induced by allergen (24, 27) , parainfluenza virus (3) and ozone (36) .
The PDE4-inhibitor, rolipram, or the corticosteroid, dexamethasone, prevented both the NO-deficiency and the AHR after LPS exposure (10) . Furthermore, the LPSinduced AHR coincided with reduced lung levels of cAMP and cGMP (38) . Together this data suggests that in this model, the LPS-induced AHR and associated NOdeficiency share common pro-inflammatory mechanisms, presumably interrelated with the associated deficiency in lung cyclic nucleotide generation.
The effectiveness of sildenafil in reversing male erectile dysfunction is due to potentiation of endogenous NO-mediated vascular relaxation in the corpus cavernosum (1). This is due to cGMP, generated by NO, being elevated through PDE5 inhibition. Thus, it was of interest to determine whether the beneficial effects of sildenafil observed against the inflammatory consequences of an LPS challenge were dependent upon endogenous levels of NO. 2h after L-NAME (4h after saline) there was a predictable elimination of NO (metabolites) confirming the effectiveness of NOS inhibition. At 4h after LPS followed by L-NAME, however, the NO levels were markedly reduced and there was now AHR to histamine at 4h after LPS. Sildenafil treatment of guinea-pigs challenged with L-NAME, prevented the L-NAME-induced reduction of NO, in both saline-and LPS-exposed animals at 4h. The levels of NO were elevated above that for LPS exposure alone at 4h and the extension of AHR to 4h after LPS seen after L-NAME treatment was inhibited by sildenafil. No inhibition of the bronchoconstrictor response to the larger dose of histamine (3mM) was observed after sildenafil treatment in L-NAME-exposed animals. Therefore, loss of AHR was not due to bronchodilatation from elevation of cGMP levels by sildenafil.
Therefore, increasing cGMP with sildenafil reversed the associated AHR and L-NAME-induced NO-deficiency. A possible mechanism for this is via a feedback mechanism of cGMP on NOS-derived NO. A deficiency in NO, below normal physiological levels, may activate the machinery to induce the expression of iNOS and other nuclear transcription factor-KB (NF-κB)-dependent pro-inflammatory mediators (31, 33) . In this study, inhibiting NO production with L-NAME appeared to elevate BALF macrophages, at 4h after LPS or saline exposure, by 4-and 5-fold, respectively, but failed to further increase the elevated levels of neutrophils after LPS exposure. However, in animals treated with sildenafil and exposed to LPS followed by L-NAME, the BALF content of macrophages and neutrophils were significantly attenuated. These findings suggest that NO-deficiency may contribute to an airways influx of leukocytes after inflammatory provocation. Thus, as sildenafil restores the L-NAME-induced NO-deficiency in both saline-and LPS-exposed animals, it is plausible that sildenafil suppresses leukocyte recruitment into the airways (and AHR) by restoring the NO or cGMP pathways. These opposing effects of lowered NO (L-NAME) and raised cGMP levels (sildenafil) on leukocyte infiltration, may also arise from changes in microvascular permeability and adhesion of leukocytes (2, 13, 32) .
In summary, sildenafil attenuated airway hyperreactivity, inflammation and NO dysfunction, in two conscious guinea-pig models. The effectiveness of sildenafil does not appear to depend upon endogenous NO levels as it does in erectile dysfunction, since inhibition of NOS with L-NAME does not prevent the action of sildenafil. That 
Figure 2
Changes in airway responsiveness to histamine (1 or 3mM, nose-only, 20s) in conscious OA-exposed (100 µg.ml 
Figure 7
Effects of L-NAME on A) differential cell (macrophage, eosinophil and neutrophil) counts and B) levels of combined nitric oxide (NO) metabolites (nitrate and nitrite) recovered in the bronchoalveolar fluid (BALF) from non-sensitised guinea-pigs 1 or 4h after exposure to LPS (30 µg.ml -1 , 1h) or saline. Guinea-pigs were either not exposed (naïve) or exposed to saline (LPS vehicle) or LPS and lavaged 1 or 4h later.
Effects of L-NAME challenge (12mM, 15 min) given 2h after saline or LPS with or without sildenafil treatment were examined on lavage performed 4h after the saline or analysed for each animal, at each time point. Before all experiments, the animals were handled and familiarised with the apparatus to reduce stress.
OA (allergen) exposure of OA-sensitisation guinea-pigs
In allergen studies, guinea-pigs were actively sensitised by intraperitoneal (i.p.)
injection of ovalbumin (OA, 10µg) and aluminium hydroxide (100mg), in 1 ml of pathogen-free saline, as described previously (24) . All procedures were commenced 14 days later. The OA-sensitised animals were exposed for 1h to a nebulised solution of OA (100 µg.ml -1 ) or the OA vehicle (0.9 % pathogen-free saline) in a sealed chamber (diameter: 700mm; depth: 160mm). A Wright nebuliser, supplied with air at a pressure of 20 lb.p.s.i., was used to deliver the aerosol at a rate of 0.5 ml.min -1 . Any animal observed to be in respiratory distress was immediately removed and the exposure was considered complete. The average of two determinations of sG aw was obtained prior to exposure, and then at regular intervals up to 12h and at 24h after the exposure.
Lipopolysaccharide exposure
In the inhaled LPS studies, non-sensitised guinea-pigs were exposed for 1h to a nebulised solution of LPS (30 µg.ml -1 ) or the LPS vehicle (0.9 % pathogen-free saline) in a sealed chamber (diameter: 700mm; depth: 160mm), as previously described (19) . A Wright nebuliser, supplied with air at a pressure of 20 lb.p.s.i., was used to deliver the aerosol at a rate of 0.5 ml.min -1 . The average of two measurements of sG aw was recorded prior to exposure (baseline) and then at regular intervals (0, 15, 30 min and hourly) after the exposure. 
L-NAME exposure
Nebulised L-NAME (12mM, 15 min) was delivered as a whole-body exposure (chamber: 300 x 200 x 150mm), to untreated or sildenafil-treated non-sensitized animals or at 105 min after completing exposures to LPS or vehicle, as previously described (19) . A Wright nebuliser, supplied with air at a pressure of 20 lb.p.s.i., was used to deliver the aerosol at a rate of 0.5 ml.min -1 . This inhaled dose of L-NAME was based upon that used by others to inhibit nitric oxide production without any significant effect on cardiovascular parameters (22) . Measurements of sG aw were taken throughout the experiment.
Airway reactivity to inhaled histamine
In allergen studies, airway reactivity to nebulised histamine (1mM, 20s), delivered as a nose-only exposure was assessed 24h before and in the same animal at 24h after OA or saline exposure in OA-sensitised guinea-pigs. In studies of non-sensitised guineapigs, airway reactivity to inhaled histamine was assessed 24h before and in the same animal at 1 or 4h after LPS or saline exposure, and at 2h after completing the exposure to L-NAME (4h after LPS exposure). This dose of histamine caused a small threshold bronchoconstriction in naïve non-sensitised guinea-pigs. To determine if the effects of sildenafil on OA-, LPS-and L-NAME-induced AHR were due to a bronchodilator activity exerting functional antagonism of the histamine-induced bronchoconstriction, a higher dose of inhaled histamine (3mM, 20s) was used. This dose of histamine, causing a significant bronchoconstriction, was used 24h before and at 24h after saline exposure in OA-sensitised guinea-pigs treated with sildenafil. This dose was also used in non-sensitised sildenafil-treated animals, before and at 1h after saline exposure or at 4h after saline exposure with a prior exposure to L-NAME. 43 Measurements of sG aw were taken before and at 0, 5 and 10 min after exposure to the histamine (1 or 3mM).
Administration of sildenafil
Animals were dosed (i.p.) with sildenafil (1 mg.kg -1 ) or the sildenafil vehicle (pathogen-free saline) at 24 and 0.5h before OA and at 24 and 0.5h before LPS or saline exposure, with and without subsequent exposure to L-NAME. OA-exposed animals were further treated at 6h. Previous experience with this model suggested that dosing at 6h improves the therapeutic efficacy of PDE-inhibitors (9) . This dose of sildenafil was based on human oral doses that showed no adverse effect (26) .
Bronchoalveolar lavage
At 24h after exposing OA-sensitised guinea-pigs to OA or saline, and at 1, 4 or 24h after LPS or saline exposure, or 4h after exposure to LPS or saline followed at 2h by L-NAME exposure in non-sensitised guinea-pigs, the animals underwent a bronchoalveolar lavage. Guinea-pigs were overdosed with pentobarbitone sodium (400 mg.kg -1 , i.p., Euthatal ® ) and the trachea cannulated. Saline (0.9 % NaCl, 1 ml.100g -1 body weight) was flushed into the lungs, and recovered 3 min later. This procedure was then repeated. A total cell count (cells.sample -1 ) of the pooled bronchoalveolar lavage fluid (BALF) from each animal was determined using a Neubauer haemocytometer. The lavage fluid samples were centrifuged (Shandon Centrifuge, Runcorn, Cheshire, UK) at 1000 r.p.m. for 7 min onto glass microscope slides. The cytospin smear was then differentially stained with Leishman's stain (1.5 % in 100 % methanol) and a minimum of 500 cells (macrophages, eosinophils and neutrophils) were counted. Lymphocytes were not identified or counted. In all the 44 groups studied there was no significant difference in the volumes of reclaimed BALF (typically, 70 -80 % recovery). The remaining BALF sample was then centrifuged (1200 r.p.m.) for 6 min, and the supernatant was removed and frozen (-70 °C), for the determination of airway NO generation.
Measurements of nitric oxide production
A spectrophotometric assay was used to determine the stable decomposition products of NO (nitrite and nitrate) in BALF. The assay was based on the Griess reaction (24) as previously described (10, 11, 23) . Briefly, 100µl samples of the BALF were standard conditions, all the samples to be compared were assayed at the same time.
The maximum linear limit of detection for the assay was 1mM. 
Statistical Analysis
To reduce inter-subject variability, changes in sGaw from the baseline sGaw values taken before a procedure, are presented as a percentage of the mean baseline value proceeding OA, LPS, saline or histamine challenges. Absolute values of baseline sGaw are stated in the figure legends. Significance of differences in the number of BAL fluid cells and NO metabolites were compared using analysis of variance, followed by Scheffe's post hoc analysis. Changes in airway function over the entire time-course were compared using analysis of variance followed by the appropriate paired or unpaired Student's (two-tailed) t-test. Differences were considered statistically significant when p<0.05.
